90Nb - A potential PET nuclide: Production and labeling of monoclonal antibodies

Radiochimica Acta

Volumn 100, Issue 11, 2012, Pages 857-863

  Radchenko, V ^a   Hauser, H ^b   Eisenhut, M ^b   Vugts, D J ^c   Van Dongen, G A M S ^c   Roesch, F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Desferrioxamine; Immuno PET; Monoclonal antibodies; Niobium 91; P isothiocyanatobenzyl desferrioxamine; Radiolabeling; TFP N succinyl desferrioxamine

Indexed keywords

EID: 84871184766     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2012.1971     Document Type: Article

References (23)

1. Wu, A. M., Olafsen, T.: Antibodies for molecular imaging of cancer. Cancer J. 14, 191 (2008).
2. US Food and Drug Administration, US Department of Health and Human Services, available from http://www.fda.gov (2010).
3. Grillo-Lopez, A. J., White, C. A., Dallaire, B. K., Varns, C. L., Shen, C. G., Wei, A., Leonard, J. E., McClure, A., Weaver, L., Cairelli, S., Rosenberg, J.: Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1, 1 (2000).
4. van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge,M. N., de Vries, E. G., Perk, L. R.: Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 12, 1379 (2007).
5. Nayak, T. K., Brechbiel,M.W.: Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem. 20, 825 (2009).
6. Qaim, S. M.: Decay data and production yields of some nonstandard positron emitters used in PET. Q. J. Nucl. Med. Mol. Imaging 52, 111 (2008).
7. Qaim, S. M.: Development of novel positron emitters for medical applications: nuclear and radiochemical aspects. Radiochim. Acta 99, 611 (2011).
8. Perk, L. R., Visser, O. J., Stigter-van Walsum, M., Vosjan, M. J. V. D., Visser, G. V. M., Zijlstra, J. M., Huijgens, P. C., van Dongen, G. A. M. S.: Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33, 1337 (2006).
9. Börjesson, P. K., Jauw, Y. W., Boellaard, R., de Bree, R., Comans, E. F. I., Roos, J. C., Castelijns, J. A., Vosjan, M. J. V. D., Kummer, J. A., Leemans, C. R., Lammerstma, A. A., van Dongen, G. A. M. S.: Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Canc. Res. 12, 2133 (2006).
10. Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Goenen,M., Ruan, S., Pierre, C., Nagel, A., Pryma, D. A., Humm, J., Larson, S. M., Old, L. J., Russo, P.: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 8, 304 (2007).
11. Deffar, K., Hengliang, S., Liang, L., Wang, X., Zhu, X.: Nanobodies -the new concept in antibody engineering. African J. Biotechnol. 8, 2645 (2009).
12. Eder, M., Knackmuss, S., Le Gall, F., Reusch, U., Rybin, V., Little, M., Haberkorn, U., Mier, W., Eisenhut,M.: 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur. J. Nucl. Med. Mol. Imaging 37, 1397 (2010).
13. Paudyal, B., Paudyal, P., Oriuchi, N., Hanaoka, H., Tominaga, H., Endo, K.: Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci. 102, 117 (2011).
14. Herzog, H., Rösch, F., Stöcklin, G., Lueders, C., Qaim, S. M., Feinendegen,L. E.: Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J. Nucl. Med. 34, 2222 (1993).
15. Rossin, R., Berndorff, D., Friebe,M., Dinkelborg, L. M., Welch, M. J.: Small-animal PET of tumor angiogenesis using a 76Brlabeled human recombinant antibody fragment to the ED-B domain of fibronectin. J. Nucl. Med. 48, 1172 (2007).
16. Browne, E., Firestone, R. B.: Table of Radioactive Isotopes. Lawrence Berkeley Laboratory, University of California, Berkeley, CA (1986).
17. Qaim, S. M., Bisinger, T., Hilgers, K., Nayak, D., Coenen, H. H.: Positron emission intensities in the decay of 64Cu, 76Br and 124I. Radiochim. Acta 95, 67 (2007).
18. Busse, S., Brockmann, J., Roesch, F.: Radiochemical separation of no-carrier-added radioniobium from zirconium targets for application of 90Nb-labelled compounds. Radiochim. Acta 90, 411 (2002).
19. Busse, S., Roesch, F., Qaim, S. M.: Cross section data for the production of the positron emitting niobium isotope 90Nb via the 90Zr(p, n)-reaction. Radiochim. Acta 90, 1 (2002).
20. Busse, S.: Produktion, radiochemische Abtrennung und koordinative Kopplung von 90Nb zur Synthese potentieller Radiopharmaka für die Positronenemissionstomographie. Ph D. Thesis, Univeristy of Mainz (2000).
21. Verel, I., Visser, G. W. M., Boellaard, R., van Walsum, S. M., Snow, G. B., van Dongen, G. A. M. S. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44, 1271 (2003).
22. Perk, L. R., Vosjan,M. J., Visser, G. W., Budde, M., Jurek, P., Kiefer, G. E., van Dongen, G. A. M. S.: p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 250 (2009).
23. Meares, C. F., McCall,M. J., Reardan,D. T., Goodwin,D. A., Diamanti, C. I., McTique,M.: Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142, 68 (1984).